{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:22:10Z","timestamp":1785280930570,"version":"3.55.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,11,17]],"date-time":"2017-11-17T00:00:00Z","timestamp":1510876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,11,17]],"date-time":"2017-11-17T00:00:00Z","timestamp":1510876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with type 2 diabetes mellitus (T2DM) experience many cardiovascular complications. Several studies have demonstrated the cardioprotective effects of incretin-based therapies; however, there are few studies on the effects of long-term incretin-based therapies on cardiovascular events. Therefore, the present study conducted a systematic review and network meta-analysis to evaluate the effects of long-term incretin-based therapies on ischaemic diseases. We searched PubMed, CENTRAL, and Clinicaltrial.gov to retrieve randomised control trials reported until December 2016 and enrolled only RCTs with more than a 1-year follow-up. The network meta-analysis was performed using R Software with a GeMTC package. A total of 40 trials were included. Dipeptidyl peptidase 4 inhibitors and glucagon-like peptide-1 agonists were associated with a lower risk of myocardial infarction (MI) than were sulfonylureas (odds ratio [95% credible interval] 0.41 [0.24\u20130.71] and 0.48 [0.27\u20130.91], respectively). These results suggested that patients with T2DM receiving long-term incretin-based therapies have a lower risk of MI than do those receiving sulfonylurea-based therapy. These findings highlight the risks of cardiovascular events in patients who receive long-term incretin-based therapies, and may provide evidence for the selection of antidiabetic therapy in the future.<\/jats:p>","DOI":"10.1038\/s41598-017-16101-1","type":"journal-article","created":{"date-parts":[[2017,11,13]],"date-time":"2017-11-13T12:40:19Z","timestamp":1510576819000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Effect of Long-term Incretin-Based Therapies on Ischemic Heart Diseases in Patients with Type 2 Diabetes Mellitus: A Network Meta-analysis"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4029-9097","authenticated-orcid":false,"given":"Che-Yi","family":"Chou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Tzu","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Lian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiun-Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsui-Er","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruey-Yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Chuan","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,17]]},"reference":[{"issue":"Suppl 2","key":"16101_CR1","doi-asserted-by":"publisher","first-page":"S145","DOI":"10.2337\/dc11-s209","volume":"34","author":"M Laakso","year":"2011","unstructured":"Laakso, M. Heart in diabetes: a microvascular disease. Diabetes care \n                           34(Suppl 2), S145\u2013149, https:\/\/doi.org\/10.2337\/dc11-s209 (2011).","journal-title":"Diabetes care"},{"key":"16101_CR2","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","author":"ntensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","year":"1998","unstructured":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet (London, England) \n                           352, 837\u2013853 (1998).","journal-title":"Lancet (London, England)"},{"key":"16101_CR3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/nyas.12044","volume":"1281","author":"F Giorgino","year":"2013","unstructured":"Giorgino, F., Leonardini, A. & Laviola, L. Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials. Annals of the New York Academy of Sciences \n                           1281, 36\u201350, https:\/\/doi.org\/10.1111\/nyas.12044 (2013).","journal-title":"Annals of the New York Academy of Sciences"},{"key":"16101_CR4","doi-asserted-by":"publisher","first-page":"d4169","DOI":"10.1136\/bmj.d4169","volume":"343","author":"R Boussageon","year":"2011","unstructured":"Boussageon, R. et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. Bmj \n                           343, d4169, https:\/\/doi.org\/10.1136\/bmj.d4169 (2011).","journal-title":"Bmj"},{"key":"16101_CR5","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1056\/NEJMoa072761","volume":"356","author":"SE Nissen","year":"2007","unstructured":"Nissen, S. E. & Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. The New England journal of medicine \n                           356, 2457\u20132471, https:\/\/doi.org\/10.1056\/NEJMoa072761 (2007).","journal-title":"The New England journal of medicine"},{"key":"16101_CR6","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1001\/archinternmed.2010.207","volume":"170","author":"SE Nissen","year":"2010","unstructured":"Nissen, S. E. & Wolski, K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Archives of internal medicine \n                           170, 1191\u20131201, https:\/\/doi.org\/10.1001\/archinternmed.2010.207 (2010).","journal-title":"Archives of internal medicine"},{"key":"16101_CR7","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2337\/dc06-1789","volume":"30","author":"AS Gangji","year":"2007","unstructured":"Gangji, A. S., Cukierman, T., Gerstein, H. C., Goldsmith, C. H. & Clase, C. M. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes care \n                           30, 389\u2013394, https:\/\/doi.org\/10.2337\/dc06-1789 (2007).","journal-title":"Diabetes care"},{"key":"16101_CR8","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1111\/j.1742-1241.2006.01178.x","volume":"60","author":"A Barnett","year":"2006","unstructured":"Barnett, A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. International journal of clinical practice \n                           60, 1454\u20131470, https:\/\/doi.org\/10.1111\/j.1742-1241.2006.01178.x (2006).","journal-title":"International journal of clinical practice"},{"key":"16101_CR9","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/cvr\/cvw216","volume":"112","author":"MV Basalay","year":"2016","unstructured":"Basalay, M. V. et al. Glucagon-like peptide-1 (GLP-1) mediates cardioprotection by remote ischaemic conditioning. Cardiovascular research \n                           112, 669\u2013676, https:\/\/doi.org\/10.1093\/cvr\/cvw216 (2016).","journal-title":"Cardiovascular research"},{"key":"16101_CR10","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1161\/CIRCULATIONAHA.107.739938","volume":"117","author":"K Ban","year":"2008","unstructured":"Ban, K. et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation \n                           117, 2340\u20132350, https:\/\/doi.org\/10.1161\/circulationaha.107.739938 (2008).","journal-title":"Circulation"},{"key":"16101_CR11","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1161\/01.CIR.0000120505.91348.58","volume":"109","author":"LA Nikolaidis","year":"2004","unstructured":"Nikolaidis, L. A. et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation \n                           109, 962\u2013965, https:\/\/doi.org\/10.1161\/01.cir.0000120505.91348.58 (2004).","journal-title":"Circulation"},{"key":"16101_CR12","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/dom.12000","volume":"15","author":"M Monami","year":"2013","unstructured":"Monami, M., Ahren, B., Dicembrini, I. & Mannucci, E. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes, obesity & metabolism \n                           15, 112\u2013120, https:\/\/doi.org\/10.1111\/dom.12000 (2013).","journal-title":"Diabetes, obesity & metabolism"},{"key":"16101_CR13","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/dmrr.2804","volume":"32","author":"T Wang","year":"2016","unstructured":"Wang, T., Wang, F., Zhou, J., Tang, H. & Giovenale, S. Adverse effects of incretin-based therapies on major cardiovascular and arrhythmia events: meta-analysis of randomized trials. Diabetes\/metabolism research and reviews \n                           32, 843\u2013857, https:\/\/doi.org\/10.1002\/dmrr.2804 (2016).","journal-title":"Diabetes\/metabolism research and reviews"},{"key":"16101_CR14","doi-asserted-by":"publisher","first-page":"e0153502","DOI":"10.1371\/journal.pone.0153502","volume":"11","author":"JY Kim","year":"2016","unstructured":"Kim, J. Y., Yang, S., Lee, J. I. & Chang, M. J. Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis. PloS one \n                           11, e0153502, https:\/\/doi.org\/10.1371\/journal.pone.0153502 (2016).","journal-title":"PloS one"},{"key":"16101_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12325-016-0432-4","volume":"34","author":"E Mannucci","year":"2017","unstructured":"Mannucci, E. & Monami, M. Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials. Advances in therapy \n                           34, 1\u201340, https:\/\/doi.org\/10.1007\/s12325-016-0432-4 (2017).","journal-title":"Advances in therapy"},{"key":"16101_CR16","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ijcard.2016.12.113","volume":"230","author":"AN Mahmoud","year":"2017","unstructured":"Mahmoud, A. N. et al. Cardiovascular safety of incretin-based therapy for type 2 diabetes: A meta-analysis of randomized trials. International journal of cardiology \n                           230, 324\u2013326, https:\/\/doi.org\/10.1016\/j.ijcard.2016.12.113 (2017).","journal-title":"International journal of cardiology"},{"key":"16101_CR17","unstructured":"Higgins JPT, G. S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration (2011)."},{"key":"16101_CR18","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton, B. et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Annals of internal medicine \n                           162, 777\u2013784, https:\/\/doi.org\/10.7326\/M14-2385 (2015).","journal-title":"Annals of internal medicine"},{"key":"16101_CR19","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins, J. P. et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. Bmj \n                           343, d5928, https:\/\/doi.org\/10.1136\/bmj.d5928 (2011).","journal-title":"Bmj"},{"key":"16101_CR20","unstructured":"Centre, T. N. C. The Cochrane Collaboration.Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre. The Cochrane Collaboration (2014)."},{"key":"16101_CR21","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1002\/sim.1189","volume":"21","author":"DE Warn","year":"2002","unstructured":"Warn, D. E., Thompson, S. G. & Spiegelhalter, D. J. Bayesian random effects meta-analysis of trials with binary outcomes: methods for the absolute risk difference and relative risk scales. Statistics in medicine \n                           21, 1601\u20131623, https:\/\/doi.org\/10.1002\/sim.1189 (2002).","journal-title":"Statistics in medicine"},{"key":"16101_CR22","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1023\/A:1008929526011","volume":"10","author":"DJ Lunn","year":"2000","unstructured":"Lunn, D. J., Thomas, A., Best, N. & Spiegelhalter, D. WinBUGS - A Bayesian modelling framework: Concepts, structure, and extensibility. Statistics and Computing \n                           10, 325\u2013337, https:\/\/doi.org\/10.1023\/A:1008929526011 (2000).","journal-title":"Statistics and Computing"},{"key":"16101_CR23","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1167","volume":"7","author":"G van Valkenhoef","year":"2016","unstructured":"van Valkenhoef, G., Dias, S., Ades, A. E. & Welton, N. J. Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis. Research synthesis methods \n                           7, 80\u201393, https:\/\/doi.org\/10.1002\/jrsm.1167 (2016).","journal-title":"Research synthesis methods"},{"key":"16101_CR24","doi-asserted-by":"publisher","unstructured":"Hemmingsen, B. et al. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus. The Cochrane database of systematic reviews, Cd009008, https:\/\/doi.org\/10.1002\/14651858.CD009008.pub2 (2013).","DOI":"10.1002\/14651858.CD009008.pub2"},{"key":"16101_CR25","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/dom.12116","volume":"15","author":"M Monami","year":"2013","unstructured":"Monami, M., Genovese, S. & Mannucci, E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes, obesity & metabolism \n                           15, 938\u2013953, https:\/\/doi.org\/10.1111\/dom.12116 (2013).","journal-title":"Diabetes, obesity & metabolism"},{"key":"16101_CR26","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1093\/eurheartj\/ehr077","volume":"32","author":"TK Schramm","year":"2011","unstructured":"Schramm, T. K. et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. European heart journal \n                           32, 1900\u20131908, https:\/\/doi.org\/10.1093\/eurheartj\/ehr077 (2011).","journal-title":"European heart journal"},{"key":"16101_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-12-3","volume":"12","author":"SS Engel","year":"2013","unstructured":"Engel, S. S. et al. Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovascular diabetology \n                           12, 3, https:\/\/doi.org\/10.1186\/1475-2840-12-3 (2013).","journal-title":"Cardiovascular diabetology"},{"key":"16101_CR28","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1111\/dom.12093","volume":"15","author":"WB White","year":"2013","unstructured":"White, W. B. et al. Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus. Diabetes, obesity & metabolism \n                           15, 668\u2013673, https:\/\/doi.org\/10.1111\/dom.12093 (2013).","journal-title":"Diabetes, obesity & metabolism"},{"key":"16101_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-11-3","volume":"11","author":"OE Johansen","year":"2012","unstructured":"Johansen, O. E., Neubacher, D., von Eynatten, M., Patel, S. & Woerle, H. J. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovascular diabetology \n                           11, 3, https:\/\/doi.org\/10.1186\/1475-2840-11-3 (2012).","journal-title":"Cardiovascular diabetology"},{"key":"16101_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6823-10-7","volume":"10","author":"D Williams-Herman","year":"2010","unstructured":"Williams-Herman, D. et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC endocrine disorders \n                           10, 7, https:\/\/doi.org\/10.1186\/1472-6823-10-7 (2010).","journal-title":"BMC endocrine disorders"},{"key":"16101_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-016-0260-0","volume":"16","author":"L Li","year":"2016","unstructured":"Li, L. et al. Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies. BMC cardiovascular disorders \n                           16, 91, https:\/\/doi.org\/10.1186\/s12872-016-0260-0 (2016).","journal-title":"BMC cardiovascular disorders"},{"key":"16101_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-016-0355-z","volume":"15","author":"KC Ferdinand","year":"2016","unstructured":"Ferdinand, K. C., Botros, F. T., Atisso, C. M. & Sager, P. T. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events. Cardiovascular diabetology \n                           15, 38, https:\/\/doi.org\/10.1186\/s12933-016-0355-z (2016).","journal-title":"Cardiovascular diabetology"},{"key":"16101_CR33","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.diabres.2012.09.004","volume":"98","author":"F Sun","year":"2012","unstructured":"Sun, F. et al. Cardiovascular safety and glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus: a pairwise and network meta-analysis. Diabetes research and clinical practice \n                           98, 386\u2013395, https:\/\/doi.org\/10.1016\/j.diabres.2012.09.004 (2012).","journal-title":"Diabetes research and clinical practice"},{"key":"16101_CR34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/jcpt.12102","volume":"39","author":"S Wu","year":"2014","unstructured":"Wu, S. et al. The cardiovascular effects of glucagon-like peptide-1 receptor agonists: a trial sequential analysis of randomized controlled trials. Journal of clinical pharmacy and therapeutics \n                           39, 7\u201313, https:\/\/doi.org\/10.1111\/jcpt.12102 (2014).","journal-title":"Journal of clinical pharmacy and therapeutics"},{"key":"16101_CR35","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1177\/1060028016663218","volume":"50","author":"J Wroge","year":"2016","unstructured":"Wroge, J. & Williams, N. T. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders. The Annals of pharmacotherapy \n                           50, 1041\u20131050, https:\/\/doi.org\/10.1177\/1060028016663218 (2016).","journal-title":"The Annals of pharmacotherapy"},{"key":"16101_CR36","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.amjcard.2012.04.061","volume":"110","author":"HR Patil","year":"2012","unstructured":"Patil, H. R. et al. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. The American journal of cardiology \n                           110, 826\u2013833, https:\/\/doi.org\/10.1016\/j.amjcard.2012.04.061 (2012).","journal-title":"The American journal of cardiology"},{"key":"16101_CR37","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1007\/s00125-011-2241-2","volume":"54","author":"M Nagashima","year":"2011","unstructured":"Nagashima, M. et al. Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice. Diabetologia \n                           54, 2649\u20132659, https:\/\/doi.org\/10.1007\/s00125-011-2241-2 (2011).","journal-title":"Diabetologia"},{"key":"16101_CR38","doi-asserted-by":"publisher","first-page":"146","DOI":"10.2337\/diabetes.54.1.146","volume":"54","author":"AK Bose","year":"2005","unstructured":"Bose, A. K., Mocanu, M. M., Carr, R. D., Brand, C. L. & Yellon, D. M. Glucagon-like peptide 1 can directly protect the heart against ischemia\/reperfusion injury. Diabetes \n                           54, 146\u2013151 (2005).","journal-title":"Diabetes"},{"key":"16101_CR39","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-015-0476-7","volume":"110","author":"E Robinson","year":"2015","unstructured":"Robinson, E. et al. Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix. Basic research in cardiology \n                           110, 20, https:\/\/doi.org\/10.1007\/s00395-015-0476-7 (2015).","journal-title":"Basic research in cardiology"},{"key":"16101_CR40","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.jacc.2014.11.043","volume":"65","author":"E Akiyama","year":"2015","unstructured":"Akiyama, E. et al. Decreased plasma levels of active glucagon-like peptide-1 in coronary artery disease. Journal of the American College of Cardiology \n                           65, 754\u2013755, https:\/\/doi.org\/10.1016\/j.jacc.2014.11.043 (2015).","journal-title":"Journal of the American College of Cardiology"},{"key":"16101_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-015-0279-z","volume":"14","author":"R Simo","year":"2015","unstructured":"Simo, R. et al. Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular diabetology \n                           14, 116, https:\/\/doi.org\/10.1186\/s12933-015-0279-z (2015).","journal-title":"Cardiovascular diabetology"},{"key":"16101_CR42","doi-asserted-by":"publisher","first-page":"e0177646","DOI":"10.1371\/journal.pone.0177646","volume":"12","author":"G Lee","year":"2017","unstructured":"Lee, G. et al. Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis. PloS one \n                           12, e0177646, https:\/\/doi.org\/10.1371\/journal.pone.0177646 (2017).","journal-title":"PloS one"},{"key":"16101_CR43","unstructured":"Antman, E. M. & Loscalzo, J. In Harrison\u2019s Principles of Internal Medicine, 19e (eds Dennis Kasper et al.) (McGraw-Hill Education, 2015)."},{"key":"16101_CR44","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/dme.13185","volume":"34","author":"ME Shomali","year":"2017","unstructured":"Shomali, M. E., Orsted, D. D. & Cannon, A. J. Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 receptor agonist, in African-American people with Type 2 diabetes: a meta-analysis of sub-population data from seven phase III trials. Diabetic medicine: a journal of the British Diabetic Association \n                           34, 197\u2013203, https:\/\/doi.org\/10.1111\/dme.13185 (2017).","journal-title":"Diabetic medicine: a journal of the British Diabetic Association"},{"key":"16101_CR45","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.2337\/dc14-1625","volume":"38","author":"F Giorgino","year":"2015","unstructured":"Giorgino, F., Benroubi, M., Sun, J. H., Zimmermann, A. G. & Pechtner, V. Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2). Diabetes care \n                           38, 2241\u20132249, https:\/\/doi.org\/10.2337\/dc14-1625 (2015).","journal-title":"Diabetes care"},{"key":"16101_CR46","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1016\/S0140-6736(15)60936-9","volume":"385","author":"L Blonde","year":"2015","unstructured":"Blonde, L. et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. The Lancet \n                           385, 2057\u20132066, https:\/\/doi.org\/10.1016\/s0140-6736(15)60936-9 (2015).","journal-title":"The Lancet"},{"key":"16101_CR47","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1463-1326.2010.01356.x","volume":"13","author":"A Garber","year":"2011","unstructured":"Garber, A. et al. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes, obesity & metabolism \n                           13, 348\u2013356, https:\/\/doi.org\/10.1111\/j.1463-1326.2010.01356.x (2011).","journal-title":"Diabetes, obesity & metabolism"},{"key":"16101_CR48","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00125-006-0510-2","volume":"50","author":"MA Nauck","year":"2007","unstructured":"Nauck, M. A. et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia \n                           50, 259\u2013267, https:\/\/doi.org\/10.1007\/s00125-006-0510-2 (2007).","journal-title":"Diabetologia"},{"key":"16101_CR49","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2337\/dc08-1355","volume":"32","author":"M Nauck","year":"2009","unstructured":"Nauck, M. et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes care \n                           32, 84\u201390, https:\/\/doi.org\/10.2337\/dc08-1355 (2009).","journal-title":"Diabetes care"},{"key":"16101_CR50","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1111\/dom.12382","volume":"16","author":"J Reusch","year":"2014","unstructured":"Reusch, J. et al. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin. Diabetes, obesity & metabolism \n                           16, 1257\u20131264, https:\/\/doi.org\/10.1111\/dom.12382 (2014).","journal-title":"Diabetes, obesity & metabolism"},{"key":"16101_CR51","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1185\/03007991003672551","volume":"26","author":"Y Seino","year":"2010","unstructured":"Seino, Y., Rasmussen, M. F., Nishida, T. & Kaku, K. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. Current medical research and opinion \n                           26, 1013\u20131022, https:\/\/doi.org\/10.1185\/03007991003672551 (2010).","journal-title":"Current medical research and opinion"},{"key":"16101_CR52","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.2337\/dc13-2760","volume":"37","author":"C Wysham","year":"2014","unstructured":"Wysham, C. et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes care \n                           37, 2159\u20132167, https:\/\/doi.org\/10.2337\/dc13-2760 (2014).","journal-title":"Diabetes care"},{"key":"16101_CR53","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1007\/s00125-014-3360-3","volume":"57","author":"PN Weissman","year":"2014","unstructured":"Weissman, P. N. et al. HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea. Diabetologia \n                           57, 2475\u20132484, https:\/\/doi.org\/10.1007\/s00125-014-3360-3 (2014).","journal-title":"Diabetologia"},{"key":"16101_CR54","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/j.1742-1241.2010.02353.x","volume":"64","author":"T Seck","year":"2010","unstructured":"Seck, T. et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. International journal of clinical practice \n                           64, 562\u2013576, https:\/\/doi.org\/10.1111\/j.1742-1241.2010.02353.x (2010).","journal-title":"International journal of clinical practice"},{"key":"16101_CR55","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1111\/dme.12267","volume":"30","author":"J Rosenstock","year":"2013","unstructured":"Rosenstock, J. et al. Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 diabetes. Diabetic medicine: a journal of the British Diabetic Association \n                           30, 1472\u20131476, https:\/\/doi.org\/10.1111\/dme.12267 (2013).","journal-title":"Diabetic medicine: a journal of the British Diabetic Association"},{"key":"16101_CR56","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.2337\/dc08-1984","volume":"32","author":"RA DeFronzo","year":"2009","unstructured":"DeFronzo, R. A. et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes care \n                           32, 1649\u20131655, https:\/\/doi.org\/10.2337\/dc08-1984 (2009).","journal-title":"Diabetes care"},{"key":"16101_CR57","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1753-0407.2012.00223.x","volume":"5","author":"AS Dobs","year":"2013","unstructured":"Dobs, A. S. et al. Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes. Journal of diabetes \n                           5, 68\u201379, https:\/\/doi.org\/10.1111\/j.1753-0407.2012.00223.x (2013).","journal-title":"Journal of diabetes"},{"key":"16101_CR58","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1016\/S0140-6736(12)60479-6","volume":"379","author":"B Gallwitz","year":"2012","unstructured":"Gallwitz, B. et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. The Lancet \n                           379, 2270\u20132278, https:\/\/doi.org\/10.1016\/s0140-6736(12)60479-6 (2012).","journal-title":"The Lancet"},{"key":"16101_CR59","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1111\/j.1463-1326.2011.01463.x","volume":"13","author":"E Bosi","year":"2011","unstructured":"Bosi, E., Ellis, G. C., Wilson, C. A. & Fleck, P. R. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. Diabetes, obesity & metabolism \n                           13, 1088\u20131096, https:\/\/doi.org\/10.1111\/j.1463-1326.2011.01463.x (2011).","journal-title":"Diabetes, obesity & metabolism"},{"key":"16101_CR60","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1053\/j.ajkd.2012.11.043","volume":"61","author":"JC Arjona Ferreira","year":"2013","unstructured":"Arjona Ferreira, J. C. et al. Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial. American journal of kidney diseases: the official journal of the National Kidney Foundation \n                           61, 579\u2013587, https:\/\/doi.org\/10.1053\/j.ajkd.2012.11.043 (2013).","journal-title":"American journal of kidney diseases: the official journal of the National Kidney Foundation"},{"key":"16101_CR61","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.2337\/dc12-1365","volume":"36","author":"JC Arjona Ferreira","year":"2013","unstructured":"Arjona Ferreira, J. C. et al. Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. Diabetes care \n                           36, 1067\u20131073, https:\/\/doi.org\/10.2337\/dc12-1365 (2013).","journal-title":"Diabetes care"},{"key":"16101_CR62","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0140-6736(12)60691-6","volume":"380","author":"B Gallwitz","year":"2012","unstructured":"Gallwitz, B. et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. The Lancet \n                           380, 475\u2013483, https:\/\/doi.org\/10.1016\/s0140-6736(12)60691-6 (2012).","journal-title":"The Lancet"},{"key":"16101_CR63","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/ijcp.12119","volume":"67","author":"B G\u00f6ke","year":"2013","unstructured":"G\u00f6ke, B., Gallwitz, B., Eriksson, J. G., Hellqvist, \u00c5. & Gause-Nilsson, I. Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial. International journal of clinical practice \n                           67, 307\u2013316, https:\/\/doi.org\/10.1111\/ijcp.12119 (2013).","journal-title":"International journal of clinical practice"},{"key":"16101_CR64","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/dom.12102","volume":"15","author":"J Rosenstock","year":"2013","unstructured":"Rosenstock, J., Wilson, C. & Fleck, P. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. Diabetes, obesity & metabolism \n                           15, 906\u2013914, https:\/\/doi.org\/10.1111\/dom.12102 (2013).","journal-title":"Diabetes, obesity & metabolism"},{"key":"16101_CR65","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/dom.12479","volume":"17","author":"RS Weinstock","year":"2015","unstructured":"Weinstock, R. S. et al. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study. Diabetes, obesity & metabolism \n                           17, 849\u2013858, https:\/\/doi.org\/10.1111\/dom.12479 (2015).","journal-title":"Diabetes, obesity & metabolism"},{"key":"16101_CR66","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1111\/dom.12011","volume":"14","author":"AH Barnett","year":"2012","unstructured":"Barnett, A. H. et al. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension. Diabetes, obesity & metabolism \n                           14, 1145\u20131154, https:\/\/doi.org\/10.1111\/dom.12011 (2012).","journal-title":"Diabetes, obesity & metabolism"},{"key":"16101_CR67","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s40261-013-0107-8","volume":"33","author":"AH Barnett","year":"2013","unstructured":"Barnett, A. H. et al. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy. Clinical drug investigation \n                           33, 707\u2013717, https:\/\/doi.org\/10.1007\/s40261-013-0107-8 (2013).","journal-title":"Clinical drug investigation"},{"key":"16101_CR68","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"373","author":"JB Green","year":"2015","unstructured":"Green, J. B. et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. The New England journal of medicine \n                           373, 232\u2013242, https:\/\/doi.org\/10.1056\/NEJMoa1501352 (2015).","journal-title":"The New England journal of medicine"},{"key":"16101_CR69","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.2337\/dc14-0024","volume":"37","author":"B Ahren","year":"2014","unstructured":"Ahren, B. et al. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes care \n                           37, 2141\u20132148, https:\/\/doi.org\/10.2337\/dc14-0024 (2014).","journal-title":"Diabetes care"},{"key":"16101_CR70","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/dom.12377","volume":"16","author":"S Del Prato","year":"2014","unstructured":"Del Prato, S., Camisasca, R., Wilson, C. & Fleck, P. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study. Diabetes, obesity & metabolism \n                           16, 1239\u20131246, https:\/\/doi.org\/10.1111\/dom.12377 (2014).","journal-title":"Diabetes, obesity & metabolism"},{"key":"16101_CR71","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.2337\/dc13-0663","volume":"36","author":"E Ferrannini","year":"2013","unstructured":"Ferrannini, E. et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes care \n                           36, 4015\u20134021, https:\/\/doi.org\/10.2337\/dc13-0663 (2013).","journal-title":"Diabetes care"},{"key":"16101_CR72","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.2337\/dc12-2718","volume":"36","author":"H Yki-Jarvinen","year":"2013","unstructured":"Yki-Jarvinen, H. et al. Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a\u2009\u2265\u200952-week randomized, double-blind study. Diabetes care \n                           36, 3875\u20133881, https:\/\/doi.org\/10.2337\/dc12-2718 (2013).","journal-title":"Diabetes care"},{"key":"16101_CR73","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"WB White","year":"2013","unstructured":"White, W. B. et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. The New England journal of medicine \n                           369, 1327\u20131335, https:\/\/doi.org\/10.1056\/NEJMoa1305889 (2013).","journal-title":"The New England journal of medicine"},{"key":"16101_CR74","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/dom.12461","volume":"17","author":"G Schernthaner","year":"2015","unstructured":"Schernthaner, G. et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes, obesity & metabolism \n                           17, 630\u2013638, https:\/\/doi.org\/10.1111\/dom.12461 (2015).","journal-title":"Diabetes, obesity & metabolism"},{"key":"16101_CR75","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1007\/s00125-013-3039-1","volume":"56","author":"FJ Lavalle-Gonzalez","year":"2013","unstructured":"Lavalle-Gonzalez, F. J. et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia \n                           56, 2582\u20132592, https:\/\/doi.org\/10.1007\/s00125-013-3039-1 (2013).","journal-title":"Diabetologia"},{"key":"16101_CR76","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica, B. M. et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. The New England journal of medicine \n                           369, 1317\u20131326, https:\/\/doi.org\/10.1056\/NEJMoa1307684 (2013).","journal-title":"The New England journal of medicine"},{"key":"16101_CR77","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer, M. A. et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. The New England journal of medicine \n                           373, 2247\u20132257, https:\/\/doi.org\/10.1056\/NEJMoa1509225 (2015).","journal-title":"The New England journal of medicine"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-16101-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-16101-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-16101-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T13:45:38Z","timestamp":1671803138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-16101-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,17]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["16101"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-16101-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,17]]},"assertion":[{"value":"6 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"15795"}}